Synthesis of 2H-Imidazo[2′,1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations

GPCR Inhibition in Treating Lymphoma

(2022) Marilia Barreca et al.   ACS Medicinal Chemistry Letters

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance

(2021) Zhijie Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein

(2021) Virginia Spanò et al.   MOLECULES

Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia

(2021) Junwei Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3

(2021) Hanna Cho et al.   JOURNAL OF MEDICINAL CHEMISTRY

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

(2020) Ahmad I. Antar et al.   LEUKEMIA

An overview on anti-tubulin agents for the treatment of lymphoma patients

(2020) Marilia Barreca et al.   PHARMACOLOGY & THERAPEUTICS

Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma

(2020) A. Arribas et al.   EUROPEAN JOURNAL OF CANCER

Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors

(2020) Virginia Spanò et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Discovery of the selective and efficacious inhibitors of FLT3 mutations

(2018) Yanle Zhi et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

(2017) Maria Larrosa-Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma

(2016) Virginia Spanò et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Comparative Docking Strategy to Identify Polyphenolic Derivatives as Promising Antineoplastic Binders of G-quadruplex DNA c-myc and bcl-2 Sequences

(2016) Giosuè Costa et al.   Molecular Informatics

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification

(2015) Yi-Yu Ke et al.   Scientific Reports

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

(2014) R. F. Schlenk et al.   BLOOD

Synthesis of [1,2]oxazolo[5,4-e]indazoles as antitumour agents

(2013) Paola Barraja et al.   TETRAHEDRON

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

(2013) Josep Tabernero et al.   Cancer Discovery

Synthesis and Antiproliferative Activity of the Ring System [1,2]Oxazolo[4,5-g]indole

(2012) Paola Barraja et al.   ChemMedChem

Improving the Prediction of Absolute Solvation Free Energies Using the Next Generation OPLS Force Field

(2012) Devleena Shivakumar et al.   Journal of Chemical Theory and Computation

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Synthesis of pyrrolo[3,2-h]quinolinones with good photochemotherapeutic activity and no DNA damage

(2010) Paola Barraja et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues

(2009) Paola Barraja et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

Physiochemical property space distribution among human metabolites, drugs and toxins

(2009) Varun Khanna et al.   BMC BIOINFORMATICS

Synthesis of the new ring system 6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline

(2009) Paola Barraja et al.   TETRAHEDRON LETTERS

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute